Please assess the completion status of the following clinical trial:

Trial Title: Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Criteria:~* Diagnosis of bladder cancer~* Bladder tumor discovered on cystoscopy within the past 60 days~* Invasive or non-invasive tumor~* Primary tumor may represent either an initial diagnosis or recurrent disease of any clinical stage~* No metastatic disease~* Must be an eligible candidate for a partial cystectomy, radical cystectomy, or trans-urethral resection of bladder tumor (TURBT)~* Has not undergone any treatment for superficial or invasive bladder cancer since the diagnostic cystoscopy~* TURBT or radical cystectomy is the planned curative surgical treatment~* ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%~* More than 30 days since any prior intravesical therapy or adjuvant chemotherapy~* More than 30 days since prior bladder surgery~* Biopsies are not considered surgeries~* No prior pelvic radiotherapy~* No concurrent systemic chemotherapy for any other cancer, except nonmelanoma skin cancer~* No concurrent NSAIDs (e.g., ibuprofen, naproxen, or cyclooxygenase-2 inhibitors) except =\< 81 mg aspirin per day~* Concurrent acetaminophen (Tylenol) or prescription opioids combined with acetaminophen (i.e., Percocet, Darvocet, Vicodin, Tylenol #3) allowed for pain~* No other concurrent investigational agents~* White Blood Cell (WBC) \>= 3,000/mm\^3~* Platelet count \>= 100,000/mm\^3~* Hemoglobin \>= 10 g/dL~* Alkaline phosphatase =\< upper limit of normal (ULN)~* Bilirubin =\< ULN~* Asparate Aminotransferase (AST) and Alanine Transaminase (ALT) =\< ULN~* Sodium 135-144 mmol/L (inclusive)~* Potassium 3.2-4.8 mmol/L (inclusive)~* Chloride 85-114 mmol/L (inclusive)~* Bicarbonate \>11 mEQ/dL~* Negative pregnancy test~* Fertile patients must use effective contraception~* Willing to avoid green tea beverages and green tea-containing products during study participation~* No evidence of other cancers, except nonmelanoma skin cancer~* No history of allergic reactions attributed to tea or to any of the compounds of similar chemical or biologic composition to Polyphenon E or any of the inactive ingredients in Polyphenon E capsules~* No uncontrolled intercurrent illness including, but not limited to, any of the following: Ongoing or active infection, Symptomatic congestive heart failure, Unstable angina pectoris, Cardiac arrhythmia, Psychiatric illness/social situations that would limit study compliance~* More than 24 hours since prior and no concurrent consumption of any other green tea supplements or more than 2 cups (16 oz) of green tea either through dietary sources or through nutritional supplementation~* Topical cosmetics (i.e., lotions, shampoos, makeup) that contain green tea are allowed~* Creatinine normal~* Not pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (placebo) (Type: PLACEBO_COMPARATOR): Patients receive six oral placebo capsules once daily for 14-28 days.
- Arm II (polyphenon E, placebo) (Type: EXPERIMENTAL): Patients receive four oral polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.
- Arm III (polyphenon E, trans-urethral resection or cystectomy) (Type: EXPERIMENTAL): Patients receive six oral polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete